Susquehanna International Group, LLP Cytom X Therapeutics, Inc. Transaction History

Susquehanna International Group, LLP

$641 Billion
Q4 2024

A detailed history of Susquehanna International Group, LLP transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 59,778 shares of CTMX stock, worth $37,660. This represents 0.0% of its overall portfolio holdings.

Number of Shares

59,778

Previous 10,304 480.14%

Holding current value

$37,660

Previous $12,000 408.33%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$0.86 - $1.29 $42,547 - $63,821	49,474 Added 480.14%	59,778 $61,000
Q3 2024 Nov 14, 2024	SELL	$1.12 - $1.51 $17,488 - $23,578	-15,615 Reduced 60.25%	10,304 $12,000
Q2 2024 Aug 15, 2024	SELL	$1.21 - $5.13 $1.1 Million - $4.67 Million	-910,859 Reduced 97.23%	25,919 $31,000
Q1 2024 May 07, 2024	BUY	$1.41 - $2.74 $1.27 Million - $2.46 Million	897,786 Added 2302.49%	936,778 $2.04 Million
Q4 2023 Feb 14, 2024	SELL	$1.07 - $1.55 $53,048 - $76,845	-49,578 Reduced 55.98%	38,992 $60,000
Q3 2023 Nov 14, 2023	SELL	$1.26 - $1.87 $2,106 - $3,126	-1,672 Reduced 1.85%	88,570 $114,000
Q2 2023 Aug 11, 2023	SELL	$1.41 - $1.92 $363,137 - $494,484	-257,544 Reduced 74.05%	90,242 $155,000
Q1 2023 May 16, 2023	BUY	$1.48 - $2.88 $495,234 - $963,699	334,618 Added 2541.15%	347,786 $525,000
Q4 2022 Feb 14, 2023	SELL	$1.19 - $1.91 $97 - $156	-82 Reduced 0.62%	13,168 $21,000
Q3 2022 Nov 14, 2022	SELL	$1.23 - $1.97 $28,874 - $46,245	-23,475 Reduced 63.92%	13,250 $19,000
Q2 2022 Aug 15, 2022	SELL	$1.53 - $2.89 $68,966 - $130,269	-45,076 Reduced 55.1%	36,725 $67,000
Q1 2022 May 16, 2022	SELL	$2.67 - $4.68 $119,888 - $210,141	-44,902 Reduced 35.44%	81,801 $218,000
Q4 2021 Feb 14, 2022	BUY	$3.87 - $7.39 $19,415 - $37,075	5,017 Added 4.12%	126,703 $549,000
Q3 2021 Nov 15, 2021	BUY	$4.32 - $6.43 $53,654 - $79,860	12,420 Added 11.37%	121,686 $620,000
Q2 2021 Aug 11, 2021	SELL	$6.33 - $9.91 $115,155 - $180,282	-18,192 Reduced 14.27%	109,266 $692,000
Q1 2021 May 17, 2021	BUY	$6.6 - $9.0 $746,453 - $1.02 Million	113,099 Added 787.65%	127,458 $985,000
Q4 2020 Feb 16, 2021	SELL	$6.47 - $7.9 $61,238 - $74,773	-9,465 Reduced 39.73%	14,359 $94,000
Q3 2020 Nov 16, 2020	SELL	$6.55 - $8.83 $17,992 - $24,256	-2,747 Reduced 10.34%	23,824 $158,000
Q2 2020 Aug 14, 2020	BUY	$7.4 - $14.64 $49,720 - $98,366	6,719 Added 33.85%	26,571 $221,000
Q1 2020 May 15, 2020	BUY	$3.61 - $8.6 $15,284 - $36,412	4,234 Added 27.11%	19,852 $152,000
Q4 2019 Feb 14, 2020	SELL	$5.17 - $8.91 $68,745 - $118,476	-13,297 Reduced 45.99%	15,618 $130,000
Q3 2019 Nov 14, 2019	SELL	$7.38 - $12.25 $136,854 - $227,164	-18,544 Reduced 39.07%	28,915 $213,000
Q2 2019 Aug 16, 2019	BUY	$9.35 - $11.41 $270,458 - $330,045	28,926 Added 156.08%	47,459 $532,000
Q2 2019 Aug 14, 2019	BUY	$9.35 - $11.41 $173,283 - $211,461	18,533 New	18,533 $208,000

Others Institutions Holding CTMX

# of Institutions

Shares Held

46.1M

Call Options Held

3.7K

Put Options Held

4.7K

View Full List

About CytomX Therapeutics, Inc.

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $41.5M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

More about CTMX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Cytom X Therapeutics, Inc. Transaction History